35th Anniversary Special: Nanoformulations - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

35th Anniversary Special: Nanoformulations
A look back at key nanoformulation advances and what lies ahead for nanoparticle-based drug-delivery systems.

Pharmaceutical Technology
Volume 36, Issue 7, pp. 68-69

Nanotechnology has been used to develop innovative formulations to improve bioavailability of drugs, and have found utility as carriers for either highly toxic payloads, such as chemotherapeutics, or very fragile payloads, such as proteins or nucleic acids. Panayiotis P. Constantinides, PhD, founder and principal of Biopharmaceutical and Drug Delivery Consulting, spoke to Pharmaceutical Technology about the utility of nanotechnology in formulation strategies, both past and future.

Advances in nanoparticles

PharmTech: Can you identify one or two key technical advances that have enabled the successful development of nanoparticles as drug delivery vehicles?

Panayiotis P. Constantinides, PhD, founder and principal of Biopharmaceutical and Drug Delivery Consulting, ppconstantinides@bpddc.com.
Constantinides: Within the scope of this discussion, both 1–100 nm and submicron particles (100–1000 nm) are considered as nanoparticles for both oral and non-oral drug delivery applications. The successful development of drug delivery vehicles through advances in pharmaceutical nanotechnology is certainly reflected in the marketed nanoparticulate drug products which are in the submicron range (100–1000 nm). These products include Doxil (liposomal doxorubicin, ALZA/1999), Abraxane (albumin-bound paclitaxel, Abraxis/2005) and NanoCrystal based drug products, Rapamune (Sirolimus, Wyeth/2000), Emend (aprepitant, Merck/2003) TriCor (fenofibrate, Abbott/2004), Megace ES (megestrol, Par/2004) and Invega (paliperidone palmitate, Ortho-McNeil-Janssen/2009).

Key technical advances which have enabled the successful development and commercialization of the aforementioned nanoparticulate drug products include advances in biology, materials science and particle engineering, processing, and manufacturing. Top-down and bottom-up manufacturing methods at small and large scale have been applied and tailored to the specific compound and its application. During the top-down process, high shearing homogenization or media-milling is used to reduce particle size in the presence of polymeric and surfactant stabilizers to prevent crystallization and particle growth. In the bottom-up process of manufacturing nanoparticles, the nanoparticle is created from its individual components, using precipitation, coacervation, polymerization, and hydrophobic aggregation in an effort to achieve small size by controlling the thermodynamics and kinetics of nucleation, growth, and chemical reactivity. Layer-by-layer self-assemblies using biopolymers and synthetic polymers create versatile nanostructures for drug and gene delivery. Nanoformulation is becoming an integral part of life-cycle management strategies for product line extensions and as enabling drug discovery technology for new molecular entities.

Top-down and bottom-up methods to manufacture nanoparticles have been applied to commercial products, the former for the marketed parenteral liposomal Doxil and the NanoCrystal drug products, and the latter for the albumin-bound nanoparticle Abraxane. For these drug products, advances in the characterization of nanoparticles and better understanding of how the ADME properties of compounds administered as nanoparticles are linked to particle size and surface chemistry have also contributed to their successful development and commercialization. In the case of the parenteral cancer chemotherapeutic drug products Doxil and Abraxane, key factors that have also contributed to their successful design and development were advances in nanoparticle targeting strategies based on the fundamental understanding of tumor biology principles, such as tumor vasculature and permeability, pH, and surface antigens.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here